Advanced therapy medicinal products (ATMPs) is the buzzword that has been around the industry for a while now, with hopes to revolutionise the way medical treatments are done, hopefully moving away from 'traditional disease management' to cures.
The BIA has successfully argued for a significant change in approach to the UK’s Supplementary Protection Certificate (SPC) manufacturing waiver. The BIA’s engagement with the Government was led by Andrew Hutchinson, Partner at Simmons and Simmons and member of the BIA’s Intellectual Property Advisory Committee (IPAC). Here he provides an update following the Government’s response to the consultation and publication of draft legislation.
The COVID-19 pandemic has demonstrated the importance of science and the dedication of scientists in overcoming the challenges that we face. At Exploristics, we have been involved in multiple projects relating to the development of new treatments and diagnostics.
Progress towards the development of COVID-19 vaccines continues as the Cell and Gene Therapy Catapult has stepped up to increase the UK’s capacity and capability to manufacture successful COVID-19 vaccines.
Big steps forward in the development of vaccines against COVID-19 for the UK today that the BIA and its members have been working towards for months. In a series of announcements the Government has unveiled a number of deals to secure access to 90 million doses of COVID-19 vaccine candidates. To facilitate the development of candidates, a new NHS registry has been set up to help make recruitment into clinical trials run smoothly.
I left academia after 7 years of country-switching, hopping from one top-flight academic institution to the next, always working on some form of mathematical biology. My final stop was Berlin, I was sick of moving and I was exceedingly tired of working on other people’s projects.
I was delighted to attend the launch of a $1 billion Antimicrobial Resistance (AMR) Action Fund, which aims to support vital research which hopes to bring two to four new antibiotics to market by 2030. The fund will be available to UK small and medium sized companies seeking to develop new antibiotics, those in this field will be able to apply this autumn. Find out more about the fund here.
The BIA is a supporter of the the award winning charity In2scienceUK. This year In2scienceUK has launched an ambitious Covid-19 response allowing young people across the country to gain essential skills, role models and knowledge on STEM Skills and careers. In this blog, their Development Officer Luke McKelvey tells us about the programme and how BIA members can get involved.
It was great to see NHS England agree a deal with BIA member Vertex last week, to enable their new cystic fibrosis drug combination Kaftrio available to NHS patients. This is brilliant news for the cystic fibrosis community with nine in 10 patients set to benefit from this life-transforming medicine.